Joint health care

Joint health care is one of the fields in which the company has been active longest – selecting new molecules and/or developing innovative technologies and applications for hyaluronic acid, ever a star component of the company’s portfolio.

Fifty years of research into hyaluronic acid have placed Fidia at the forefront in R&D, technological development, production and commercialization, not only in Italy but worldwide.

Fidia offers an exciting therapeutic option to the treatment of osteoarthritis, effectively controlling pain symptoms and altering the progress of the cartilage damage.

Osteoarthritis (OA) is a degenerative debilitating condition characterized by pain, joint inflammation and joint stiffness, and results in a substantial degree of physical disability, poor quality of life, negative impact on personal relationships, increase of economic burden on individuals, as well as on health and social care systems, and joint replacement surgery, when the disease becomes so severe that pain is debilitating.

Intra-articular administration of hyaluronic acid (viscosupplementation) when using the most appropriate formulation and the optimal method of administration, can provide long-lasting pain relief, reduce the chondropathy and stimulate the damaged cartilage repair, also subsequent to joint overuse, e.g. sport-related traumatic events.